Treatment of Nystagmus
The treatment of nystagmus requires a multimodal approach prioritizing correction of refractive errors and low-vision rehabilitation, with pharmacological therapy (particularly 4-aminopyridine for downbeat nystagmus) and surgical intervention reserved for specific subtypes and symptoms.
Initial Management Framework
Optical Correction (First-Line)
The foundation of nystagmus management begins with addressing refractive errors, which can significantly improve visual function 1:
- Cycloplegic refraction is essential to reveal significant refractive errors that may improve visual acuity
- Eyeglasses prescription should be verified by checking vision with and without correction to confirm measurable improvement
- Contact lenses are preferred over spectacles in infantile nystagmus, particularly when abnormal head posture, lateral gaze, or higher refractive errors are present 2
- Prism glasses can induce artificial exophoria (base-out prisms) or shift an eccentric null zone (base in direction of head posture) 2, 3
Vision Rehabilitation (Essential Component)
Prompt referral for low-vision rehabilitation services is the ophthalmologist's critical role 1:
- Binocular acuity assessment is especially important in nystagmus because it allows compensatory head posture to dampen the nystagmus
- Avoid monocular occlusion during testing as it increases latent nystagmus amplitude
- Low-vision aids should be prescribed according to magnification requirements 2
Pharmacological Treatment (Type-Specific)
The evidence supports specific medications for particular nystagmus subtypes 4, 5:
For Downbeat Nystagmus (Strongest Evidence)
- 4-aminopyridine (3 × 5 mg/d or 1-2 × 10 mg Fampridin) is the most beneficial treatment, though often unavailable 2, 3
- Alternative: Clonazepam, gabapentin, or baclofen as second-line interventions 3
For Infantile Nystagmus Syndrome
- Gabapentin (up to 2400 mg/d): Non-selective GABAergic and anti-glutamatergic effect 2, 6
- Memantine (up to 40 mg/d): Anti-glutamatergic effect 2, 6
For Periodic Alternating Nystagmus
- Baclofen (3 × 5-10 mg/d): GABA-B-receptor agonist 2
For Upbeat Nystagmus
- 4-aminopyridine (3 × 5 mg/d) or baclofen (3 × 5-10 mg/d) 2
For Acquired Pendular Nystagmus/Oculopalatal Tremor
- Gabapentin (up to 2400 mg/d) or memantine (up to 40 mg/d) 2
Surgical Intervention (For Specific Indications)
Surgery targets abnormal head posture and null zone positioning 2, 6:
- Unilateral recess-resect surgery of the dominant eye in infantile esotropia with latent nystagmus
- Kestenbaum operation of both eyes in infantile nystagmus syndrome with eccentric null zone and abnormal head posture
- Recess-resect surgery to produce artificial exophoria in infantile nystagmus syndrome
- Surgery can shift the null zone into primary position and alleviate secondary cervical spine problems
Critical Clinical Pitfalls
Avoid monocular occlusion during visual acuity testing in children with nystagmus—this increases the amplitude of latent components and artificially reduces measured acuity 1. Use a high-plus sphere as an occluder for best monocular measurement.
Differentiate infantile from acquired nystagmus by considering both time of onset and waveform characteristics 6. Neurological disease should be suspected when nystagmus is asymmetrical or unilateral, requiring neuroimaging and electrophysiology workup.
Evidence Quality Considerations
Most pharmacological studies have small sample sizes and lack long-term data, making direct comparisons challenging 4. The strongest evidence exists for 4-aminopyridine in downbeat nystagmus (two RCTs) 7. Efficacy varies significantly among individuals, necessitating personalized treatment approaches 4, 5.
All pharmacological treatments represent off-label use 2, requiring informed consent and careful monitoring for adverse effects while balancing nystagmus reduction against preservation of normal eye movements.